

ERRATUM

Open Access



Erratum to: Experiences and attitudes of residents regarding a community-based genome cohort study in Japan: a population-based, cross-sectional study

Keiko Miyamoto^{1*}, Miho Iwakuma¹ and Takeo Nakayama²

Erratum

After the publication of this article the authors noticed that an incorrect version of Table 3 is shown. The correct version can be seen on the following page.

Author details

¹Department of Medical Communication, Kyoto University School of Public Health, Yoshidakonoe-cho, Sakyo-ku, Kyoto #6068501, Japan. ²Department of Health Informatics, Kyoto University School of Public Health, Yoshidakonoe-cho, Sakyo-ku, Kyoto #6068501, Japan.

Received: 29 November 2016 Accepted: 8 December 2016

Published online: 12 January 2017

Reference

1. Keiko M, Miho I, Takeo N. Experiences and attitudes of residents regarding a community-based genome cohort study in Japan: a population-based, cross-sectional study. *BMC Med Genomics*. 2016;9:14. doi:10.1186/s12920-016-0175-8.

* Correspondence: miyamoto.keiko.87w@st.kyoto-u.ac.jp

¹Department of Medical Communication, Kyoto University School of Public Health, Yoshidakonoe-cho, Sakyo-ku, Kyoto #6068501, Japan

Table 3 Relationship between awareness of the benefit of genome study and awareness of the Nagahama study, self-rated understanding of terminology/concern, and belief of usage of genetic information in companies or government bodies from Logistic Regression Analysis

		Male (n = 704)			Female (n = 769)						
		The use of genetic information is helpful for disease treatment			The use of genetic information is helpful for disease treatment						
		Agree (n = 554)	NEW; Neutral or Disagree (n=15)	OR ^a	95%CI	P-value	Agree (n = 591)	NEW; Neutral or Disagree (n=121)	OR ^a	95%CI	P-value
		n (%)	n (%)				n (%)	n (%)			
High awareness of the Nagahama study		191 (34.8)	14 (12.4)	3.82	1.93–7.57	<0.001	326 (55.6)	40 (33.3)	2.63	1.63–4.24	<0.001
Self-rated understanding of terminology											
High		231 (41.8)	19 (16.5)	1			168 (28.8)	15 (12.6)	1		
Middle		206 (37.3)	30 (26.1)	0.66	0.34–1.29	0.223	224 (38.4)	37 (31.1)	0.72	0.36–1.42	0.342
Low		116 (21.0)	66 (57.4)	0.24	0.12–0.46	<0.001	192 (32.9)	67 (56.3)	0.49	0.27–0.98	0.045
Concerns											
Financial infusion		456 (84.0)	60 (52.2)	4.37	2.49–7.69	<0.001	473 (81.4)	65 (53.7)	2.98	1.79–4.97	<0.001
Privacy concerns		343 (62.5)	56 (49.6)	0.72	0.39–1.32	0.284	335 (56.9)	53 (43.8)	1.00	0.57–1.74	0.993
Discriminations		250 (45.3)	39 (34.2)	1.38	0.47–2.58	0.315	234 (39.9)	38 (31.4)	0.77	0.43–1.38	0.386
Unexpected negative effects		228 (41.4)	38 (33.0)	1.02	0.54–1.93	0.963	192 (32.6)	33 (27.5)	0.49	0.26–0.90	0.022
Cloned human beings		203 (37.0)	35 (30.4)	0.87	0.46–1.66	0.682	191 (32.5)	24 (20.2)	2.27	1.16–4.46	0.017
Belief											
Company or government bodies use genome information		267 (48.8)	33 (29.7)	1.35	0.77–2.36	0.299	251 (42.7)	30 (25.0)	1.71	0.98–3.00	0.060

^aAdjusted according to age and formal education duration